Aspirin chemoprevention in colorectal cancer: network meta-analysis of low, moderate, and high doses. 

Br J Surg 2023; 110: 1691-1702.

Thirteen trials (ten RCTs) were included in the analysis of almost 100,000 participants. Low and medium dose aspirin had no significant effect, but high dose aspirin (500-1200mg/day) reduced the risk of colon cancer: odds ratio 0.69, 95 per cent credible interval 0.5 to 0.96.

Comment: the higher dose of aspirin comes with risks, so although interesting, unlikely to be widely used.